nccRCC
Advertisement
Drs. Karine Tawagi and Christopher Wallis review the SUNNIFORECAST and TiNivo-2 trials at the ESMO Congress 2024.
The combination of ipilimumab/nivolumab may be a new standard in some subgroups of patients with metastatic nccRCC.
Drs. Barata and Tawagi provide updates in nccRCC, including SAMETA, PAPMET2, SUNNIFORECAST, and updated NCCN guidelines.
In anticipation of ESMO, Dr. Katy Beckermann previews various clinical trials and studies to be presented in kidney cancer.
Patients either underwent 54 weeks of treatment with everolimus 10 mg per day or treatment with a matching placebo.
The panel concludes with an overview of advancements and upcoming trials in the treatment of nccRCC.
The panel weighs the progress and challenges of adjuvant pembro and addresses the toxicity profiles of IO/TKI regimens.
The panel delves into the challenges and treatment approaches for various rare subtypes of nccRCC, including translocation.
CEUS for the assessment of nccRCC can provide a more sensitive alternative to conventional ultrasound imaging.
The panel highlights recent advancements in combination therapies for nccRCC, with a focus on KEYNOTE-B61 and cabo-nivo.
The panel focuses on CN, oligometastatic disease treatment, and advancements in systemic therapies over the past few decades.
The panel explores our understanding of nccRCC, including classification, molecular distinctions, and prognostic criteria.
A recent study that sought to characterize rare kidney tumors has identified novel biomarkers in nccRCC subtypes.
Dr. Apolo shares the trials in progress she presented at this year's meeting, including SMART, LASER, and E-VIRTUE.
Dr. Albiges comments on the latest data from the nccRCC trial KEYNOTE-B61, including an extended follow-up analysis.
The study sought to better understand the effects of first-line systemic therapy in metastatic ChRCC.
Dr. Nguyen shares an ongoing study of combination tivozanib and nivolumab in advanced non-clear cell renal cell carcinoma.
Dr. Doshi and colleagues designed an analysis of patients with metastatic ChRCC to better understand first-line therapy.
IO/IO and IO/TKI immune combination therapies are common in the first-line treatment of renal cell carcinoma.
In patients with RCC, around 20% demonstrate non-clear cell histology, including various histology types.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.